{"id":57626,"date":"2021-12-20T20:41:05","date_gmt":"2021-12-21T01:41:05","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/?p=57626"},"modified":"2023-06-06T18:17:32","modified_gmt":"2023-06-06T22:17:32","slug":"carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/","title":{"rendered":"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies"},"content":{"rendered":"<figure id=\"attachment_48118\" class=\"thumbnail wp-caption alignright\" style=\"width: 210px\"><a href=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-48118\" src=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC-200x300.jpg\" alt=\"Lisa-Carey-LCCC-ASCO-Recorded-Discussion\" width=\"200\" height=\"300\" srcset=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC-200x300.jpg 200w, https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC-301x452.jpg 301w, https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg 600w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a><figcaption class=\"caption wp-caption-text\">Lisa Carey, MD, FASCO<\/figcaption><\/figure>\n<p><a href=\"https:\/\/www.med.unc.edu\/medicine\/directory\/lisa-a-carey-md\/\">Lisa A. Carey<\/a>, MD, FASCO, the\u00a0L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Division of Oncology and Deputy Director of Clinical Sciences for the Lineberger Comprehensive Cancer Center, discusses findings from a pooled analysis of the MONALEESA-2, -3, and -7 trials. Among the findings was a consistent overall survival benefit with ribociclib plus endocrine therapy for patients with luminal A, luminal B, and HER2E breast cancer subtypes. Patients with the basal-like subtype did not derive a benefit from ribociclib, but the sample size was small (Abstract GS1-04).<\/p>\n<p><a href=\"https:\/\/ascopost.com\/videos\/2021-san-antonio-breast-cancer-symposium\/lisa-carey-on-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\">Watch her ASCO recorded discussion.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lisa A. Carey, MD, FASCO, the\u00a0L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Division of Oncology and Deputy Director of Clinical Sciences for the Lineberger Comprehensive Cancer Center, discusses findings from a pooled analysis of the MONALEESA-2, -3, and -7 trials. Among the findings was a consistent overall survival benefit with &hellip; <a href=\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\" aria-label=\"Read more about Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies\">Read more<\/a><\/p>\n","protected":false},"author":69419,"featured_media":48118,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,517,583],"tags":[630],"class_list":["post-57626","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-oncology","category-research-news","tag-630","odd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies | Department of Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies | Department of Medicine\" \/>\n<meta property=\"og:description\" content=\"Lisa A. Carey, MD, FASCO, the\u00a0L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Division of Oncology and Deputy Director of Clinical Sciences for the Lineberger Comprehensive Cancer Center, discusses findings from a pooled analysis of the MONALEESA-2, -3, and -7 trials. Among the findings was a consistent overall survival benefit with &hellip; Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Medicine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UNCDeptMedicine\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-21T01:41:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-06T22:17:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Morris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:site\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Morris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\"},\"author\":{\"name\":\"Kim Morris\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"headline\":\"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies\",\"datePublished\":\"2021-12-21T01:41:05+00:00\",\"dateModified\":\"2023-06-06T22:17:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\"},\"wordCount\":129,\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg\",\"keywords\":[\"2021\"],\"articleSection\":[\"News\",\"Oncology\",\"Research News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\",\"name\":\"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies | Department of Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg\",\"datePublished\":\"2021-12-21T01:41:05+00:00\",\"dateModified\":\"2023-06-06T22:17:32+00:00\",\"author\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg\",\"width\":600,\"height\":900,\"caption\":\"Lisa Carey, MD, FASCO\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/\",\"name\":\"Department of Medicine\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\",\"name\":\"Kim Morris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"caption\":\"Kim Morris\"},\"description\":\"Medicine - Dept of\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies | Department of Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/","og_locale":"en_US","og_type":"article","og_title":"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies | Department of Medicine","og_description":"Lisa A. Carey, MD, FASCO, the\u00a0L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Division of Oncology and Deputy Director of Clinical Sciences for the Lineberger Comprehensive Cancer Center, discusses findings from a pooled analysis of the MONALEESA-2, -3, and -7 trials. Among the findings was a consistent overall survival benefit with &hellip; Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/","og_site_name":"Department of Medicine","article_publisher":"https:\/\/www.facebook.com\/UNCDeptMedicine","article_published_time":"2021-12-21T01:41:05+00:00","article_modified_time":"2023-06-06T22:17:32+00:00","og_image":[{"width":600,"height":900,"url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","type":"image\/jpeg"}],"author":"Kim Morris","twitter_card":"summary_large_image","twitter_creator":"@uncdeptmedicine","twitter_site":"@uncdeptmedicine","twitter_misc":{"Written by":"Kim Morris","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/"},"author":{"name":"Kim Morris","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"headline":"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies","datePublished":"2021-12-21T01:41:05+00:00","dateModified":"2023-06-06T22:17:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/"},"wordCount":129,"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","keywords":["2021"],"articleSection":["News","Oncology","Research News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/","url":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/","name":"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies | Department of Medicine","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","datePublished":"2021-12-21T01:41:05+00:00","dateModified":"2023-06-06T22:17:32+00:00","author":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#primaryimage","url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","contentUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","width":600,"height":900,"caption":"Lisa Carey, MD, FASCO"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/carey-discussed-studies-hr-positive-and-her2-negative-advanced-breast-cancer-overall-survival-by-subtype-across-three-monaleesa-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/"},{"@type":"ListItem","position":2,"name":"Carey Discussed Studies of HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/","name":"Department of Medicine","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529","name":"Kim Morris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","caption":"Kim Morris"},"description":"Medicine - Dept of","url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC-200x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/12\/Lisa-Carey-LCCC-150x150.jpg","featured_image_alt":"Lisa-Carey-LCCC-ASCO-Recorded-Discussion","category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/news\/"},{"name":"Oncology","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/oncology\/"},{"name":"Research News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/research-news\/"}],"tag_details":[{"name":"2021","link":"https:\/\/www.med.unc.edu\/medicine\/news\/tag\/2021\/"}],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/57626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/users\/69419"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/comments?post=57626"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/57626\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media\/48118"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media?parent=57626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/categories?post=57626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/tags?post=57626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}